Bausch + Lomb's Age-Related Macular Degeneration Nutraceutical AREDS Formula Secures 5-Year Extension Data from the National Eye Institute
Reassessment of Standard AMD Treatment Through Large-Scale Long-Term Follow-Up
The National Eye Institute (NEI)–led AREDS and AREDS2 extension study (NCT00594672) is a clinical investigation that monitors the long‑term course of age‑related macular degeneration (AMD), the leading cause of blindness in older adults. Beyond simply measuring the effect of a nutritional supplement, the study aims to quantify the long‑term disease progression rate of AMD using patient cohorts accumulated over several decades. Notably, it re‑evaluates the long‑term preventive efficacy and safety profile of the formula that underlies commercial AMD supplements such as Bausch + Lomb’s PreserVision (BLCO), providing substantial clinical relevance. The extended follow‑up data will inform academic standards for future AMD prevention guidelines and serve as a foundation for sustained market confidence.
Precision Cohort Design for Multidimensional Biomarker Collection
The extension study is structured as a prospective cohort involving 110 participants who completed the original AREDS and AREDS2 trials, with annual ophthalmic examinations and regular monitoring. Enrolled subjects undergo precise visual acuity testing, dilated eye examinations, and yearly fundus photography to capture subtle retinal changes. In addition, blood samples are analyzed for cholesterol levels and inflammatory‑related genetic variants to explore correlations between genetic susceptibility and disease progression from multiple angles. This multidimensional data collection provides critical insights into individual patient heterogeneity, enabling the development of personalized prevention and treatment strategies.
Market Position and Commercial Potential of the Standard of Care Based on Clinical Data
Results from the original AREDS trial demonstrated that a combination of antioxidant vitamins (Vitamin C, Vitamin E, beta‑carotene) and zinc reduced the risk of late progression in patients with moderate‑to‑severe AMD by 25%. The subsequent AREDS2 formulation replaced beta‑carotene with lutein and zeaxanthin to mitigate lung‑cancer risk in smokers, and it has become the global standard of care (SOC) for AMD prevention. As of 2026, the worldwide AMD therapeutic market is estimated at $11 billion to $13 billion, with demand for preventive regimens expected to grow alongside an aging population. Demonstrating more than five years of safety in this extension study solidifies the formula as an irreplaceable primary preventive therapy and underpins the OTC revenue streams of Bausch + Lomb and other stakeholders.
Competitive Landscape with Innovative Drug Pipelines and Future Outlook
While the oral AREDS2 formula currently dominates as the preventive standard, innovative therapies are emerging in the geographic atrophy (GA) stage of advanced dry AMD, intensifying competition. Notable examples include Apellis Pharmaceuticals’ Syfovre (pegcetacoplan) and Astellas’ Izervay (avacincaptad pegol), both complement inhibitors that have received regulatory approval and are targeting the market. However, these injectable treatments face limitations in administration convenience and potential adverse events, keeping the oral AREDS2 formulation the recommended preventive option for early‑ to mid‑stage patients. Consequently, the extension study highlights the long‑term safety and cost‑effectiveness of the nutritional approach, reinforcing its role as a defensive barrier for the existing supplement market.
This study serves as a landmark by confirming the ultra‑long‑term preventive efficacy and safety profile of the AREDS formula—the only evidence‑based preventive therapy in the AMD market, which is valued at roughly $11 billion globally. For OTC players such as Bausch + Lomb (BLCO), the data provide essential scientific justification to sustain market dominance of their standard‑of‑care product line against the incursion of high‑cost C3/C5 complement‑inhibitor injectables like Apellis’s Syfovre and Astellas’s Izervay. By integrating genetic analyses with cohort data, the investigators are building a precise disease‑progression database for dry AMD, which can substantially reduce the cost and risk associated with selecting control arms in Phase 2/3 trials of novel candidates. Biomarkers and risk factors identified through long‑term follow‑up are expected to inform revisions of preventive medicine guidelines, thereby continuously driving growth of the patient‑friendly oral combination‑formula market.
Source: ClinicalTrials.gov (api_ct)